By Adam Cancryn and Sarah Owermohle
Dozens of consumer advocacy groups want the Biden administration to take drastic action on pharmaceutical prices, arguing it should be willing to break drug patents to keep costs low.
In a letter to HHS Secretary Xavier Becerra, the organizations contend the government has the power to use so-called march-in rights to create generic competition — and that Biden shouldn’t be afraid to use it.
“Any plan developed by the Department of Health and Human Services to combat excessive drug prices that does not call for the use of competitive licensing remedies would be incomplete,” the groups, including Public Citizen, Indivisible and Doctors for America, wrote. “High drug prices are rooted in monopoly power.”